IMGN 632

Drug Profile

IMGN 632

Alternative Names: Anti-CD123 antibody; IMGN632

Latest Information Update: 23 Jan 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator ImmunoGen
  • Class Drug conjugates; Immunoconjugates; Monoclonal antibodies
  • Mechanism of Action Alkylating agents; Interleukin-3-receptor-alpha-subunit-antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Haematological malignancies

Most Recent Events

  • 03 Dec 2016 Pharmacodynamics data from preclinical trials in Haematological malignancies presented at the 58th Annual Meeting and Exposition of the American Society of Haematology
  • 28 Oct 2016 Immunogen plans a clinical trial for Haematological malignancies in 2017
  • 04 Aug 2016 ImmunoGen plans to file an IND application with the US FDA for Haematological malignancies in the third quarter of 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top